Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 40 MARCUS DRIVE MELVILLE NY 11747 |
Tel: | 1-631-7608100 |
Website: | https://www.biorestorative.com |
IR: | See website |
Key People | ||
Lance Alstodt Chairman of the Board, President, Chief Executive Officer | Robert E. Kristal Chief Financial Officer | Robert Paccasassi Vice President - Quality Assurance/Regulatory Compliance | Francisco Silva Vice President - Research & Development, Secretary, Director |
Business Overview |
BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The Company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. |
Financial Overview |
For the fiscal year ended 31 December 2023, BioRestorative Therapies Inc revenues increased 22% to $146K. Net loss decreased 22% to $14.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in S decrease of 38% to $7.8M (expense), Interest income increase from $12K to $552K (income). |
Employees: | 11 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | N/A |
Annual revenue (TTM): | $0.15M as of Dec 31, 2023 |
EBITDA (TTM): | -$15.06M as of Dec 31, 2023 |
Net annual income (TTM): | -$14.42M as of Dec 31, 2023 |
Free cash flow (TTM): | -$6.60M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 6,769,919 as of Mar 28, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |